Ly2157299 (gallisertib), an anti-tumor drug, has been approved for clinical use in China

Ly2157299 (gallisertib), an antineoplastic drug of Lilly pharmaceutical, was first declared in China in December 2013 and approved for clinical use on March 31, 2015 At present, the processing status is "under approval", involving acceptance numbers: jxhl13000455 and jxhl13000456 Ly2157299 (gallisertib), the target of ly2157299, is a TGF - β receptor kinase inhibitor, which can selectively block TGF - β signal in vitro, thus improving the overall survival rate of patients Ly2157299 is currently in the phase I clinical trial stage, involving glioma, liver cancer, pancreatic cancer, myelodysplastic syndrome and other indications Preliminary tests showed that ly2157299 showed antitumor activity in different HCC models, and it has been proved that ly2157299 has good toxicity in patients with glioma Ly2157299, a good partner of PD-1 inhibitor, is superior in that it can form a compound preparation with such subversive immunotherapy as PD-1 inhibitor to assist PD-1 inhibitor to maximize its value In recent years, immunotherapy using human immune system to resist cancer has attracted much attention, among which the competition of PD-1 inhibitors is fierce: after the approval of pembrolizumab in the United States, the opdivo (nivolumab) of Bristol Myers Squibb was approved by FDA more than three months in advance Lilly pharmaceutical missed a promising immunotherapy, and now it can't miss a good opportunity to form a compound with immunotherapy So in early 2015, it signed a cooperation agreement with Bristol Myers guibaoda, combining opdivo and ly2157299, to evaluate the safety and effectiveness of the potential treatment methods for advanced glioblastoma, hepatocellular carcinoma and non-small cell lung cancer In addition, Lilly also cooperated with mosadon to conduct clinical trials to evaluate the effect of recombinant human IgG1 monoclonal antibody necitumumab combined with keytruda on non-small cell lung cancer The combination of ly2157299 and heavyweight PD-1 inhibitors may not only solve the problem of tumor heterogeneity and inevitable drug resistance, but also win a place in the $30 billion PD-1 inhibitor Market for Lilly pharmaceutical It is worth mentioning that ly2157299 has not been listed in other countries and has been approved in China The application speed and review progress are relatively fast However, the Chinese clinical application of its compound nivolumab has not been approved, and the queue number of clinical application is currently 27 digits So, it will be a long time before Lilly carries out the clinical trial of immunotherapy compound in China.